Health and Life Sciences
Exeter, Devon, EX1 2LU, United Kingdom
Location status: Recruiting
Location contact
Alistair Monteyne, PhD
CONTACT
Alistair Monteyne, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07082309
The ketone β-hydroxybutyrate (BHB) is endogenously produced during periods of low glucose availability, serving as an alternative metabolic fuel. Beyond its role as an energy substrate, BHB acts as a pleiotropic signalling molecule, modulating various physiological processes across multiple tissues. BHB can also be ingested orally as a ketone monoester, transiently elevating plasma concentrations of BHB to a level similar to those seen following several days of fasting, thereby obviating the need for dietary manipulation. The influence of BHB on human skeletal muscle protein metabolism remains poorly understood, although emerging evidence suggests that BHB may play a role in regulating muscle protein turnover. As such, BHB supplementation may support skeletal muscle remodelling and offer therapeutic benefits, and investigating this is of considerable interest. This study will investigate the ability of oral BHB ingestion - co-ingested with protein - to stimulate skeletal muscle anabolism in young healthy adults. A dual amino acid stable isotope tracer approach will be utilised to determine postprandial (i.e., fed state) muscle protein synthesis (MPS) rates and whole-body amino acid kinetics, given BHBs systemic effects. This research will advance our understanding of the fundamental biology of exogenous ketosis and provide insight into the potential of BHB supplementation as a novel nutritional strategy to optimise muscle mass and quality.
Interested in participating?
Request Info18 year–40 year
All sexes
Interventional
Not applicable
Exeter, Devon, EX1 2LU, United Kingdom
Location status: Recruiting
Alistair Monteyne, PhD
CONTACT
Alistair Monteyne, PhD
PRINCIPAL_INVESTIGATOR
The ketone body β-hydroxybutyrate (BHB) is produced endogenously during periods of low glucose availability (e.g., fasting or starvation) and provides an alternative metabolic fuel. BHB also acts as a metabolic signalling molecule, modulating physiological processes across multiple tissues, including skeletal muscle. However, the impact of exogenous ketosis on muscle protein turnover, which regulates muscle mass and modulates physical function, remains largely unexplored. As such, understanding how BHB affects skeletal muscle protein turnover is fundamentally important. The ingestion of 0.5g/kg body mass BHB appreciably increases plasma BHB concentrations for several hours, to ~3-5 mM; equivalent to several days of fasting. This offers a model to exogenously elevate plasma BHB concentrations and investigate how BHB interacts with feeding to affect postprandial protein metabolism, the period primarily responsible for driving changes in muscle quality and quantity.
An early study demonstrated that the infusion of BHB stimulates muscle protein synthesis rates (MPS), whilst only a single recent study has investigated the effect of oral BHB ingestion (exogenous ketosis) on MPS. Prior work demonstrated that the ingestion of an oral ketone monoester stimulated MPS, and it did so to a similar extent as 10 g whey protein or co-ingestion of the two, in healthy young males. While this study provides useful insights, several unanswered questions/objectives that justify the need for further investigation remain:
The aim, therefore, is to establish the effect of BHB and protein co-ingestion on myofibrillar protein synthesis rates, mitochondrial protein synthesis rates, and whole-body protein turnover. We will address this question by utilising a meal-like bolus of protein (0.3 g/kg whey protein), with and without 0.5g/kg body mass BHB (matching the test drinks caloric content via the addition of fat to minimally stimulate insulin secretion), whilst applying a dual-stable isotope tracer approach.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)
Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
Time frame: 5 hours (2 hours postabsorptive, 3 hours postprandial)
Skeletal muscle protein synthesis rates
Time frame: 5 hours
Plasma amino acid concentrations
Time frame: 5 hours (2 hours postabsorptive, 3 hours postprandial)
Whole-body kinetics of phenylalanine will be quantified using a primed continuous intravenous infusion of stable isotope-labelled phenylalanine and tyrosine tracers (e.g., L-[ring-²H₅]-phenylalanine and L-[³-¹³C]-tyrosine). Arterialised-venous blood samples will be collected at steady state to determine tracer enrichment in plasma.
The following parameters will be calculated:
Rate of appearance (Ra) of phenylalanine (μmol/kg/min), rate of disappearance (Rd) of phenylalanine (μmol/kg/min), hydroxylation rate of phenylalanine to tyrosine (μmol/kg/min) (derived from the appearance of labelled tyrosine from labelled phenylalanine), and net balance of phenylalanine (μmol/kg/min): calculated as the difference between Ra and Rd to assess overall protein balance.
Time frame: 5 hours
Serum insulin concentrations
Time frame: 5 hours
Plasma beta hydroxybutyrate concentrations
Contact information is provided by the study sponsor or research team.
University of Exeter
Other
Acronym: WAKM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07709494
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Miami, Florida, United States
View Trial DetailsNCT07700953
Healthy Participants
Wuxi, China
View Trial DetailsNCT07035769
Healthy Participants
Edegem, Belgium
View Trial DetailsNCT06564389
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Anaheim, California, United States
View Trial Details